Home Share Market Cancer test developer Accustem seeks Nasdaq uplisting, $10M offering (OTCMKTS:ACUT)

Cancer test developer Accustem seeks Nasdaq uplisting, $10M offering (OTCMKTS:ACUT)


2d illustrations and photos

Oncology diagnostics developer Accustem Sciences (OTCQB:ACUT) has filed to uplist its shares to Nasdaq and raise a proposed $10M through a public offering.

Accustem didn’t specify in its filing the number and price of the shares it plans to offer, but indicated in an attached filing fee schedule that it was looking to raise around $10M.

Shares of the diagnostics company are currently traded OTC under the symbol ACUT. The company hopes to list them on Nasdaq under the same symbol.

The company added that it may conduct a reverse stock split ahead of the deal. Think Equity is serving as lead bookrunner.

Based in New York, Accustem’s lead product, StemPrint ER, is used to predict the risk of distant recurrence in ER+ HER2- breast cancer patients. The company said that it plans to launch the product after it establishes a commercial lab and obtains US regulatory clearance for the test, a process that it expects will take at least 18 months.

With no products yet on the market, Accustem has been operating in the red. For the nine-month period ended Sept. 30, Accustem reported a net loss of $2.8M with no revenue.

In September, Accustem announced that it had received a US patent for its StemPrint ER test.



Source link

RELATED ARTICLES

Business News LIVE Today: Latest Business News, Share Market News, Economy & Finance News | Moneycontrol

By Market Capitalisation. Net Sales. Net Profit. Total Assets. Excise. Other Income. Raw Materials. Power & Fuel. Employee Cost. PBDIT. Interest. Tax. EPS. Investments. Sundry Debtors. Cash/Bank. Inventory. Debt. Contingent Liabilities. Screen Crit Abrasives Aerospace & Defence Agriculture Air Conditioners Airlines Aluminium & Aluminium Products Amusement Parks/Recreation/Club Aquaculture Auto Ancillaries Auto Ancillaries -...

Should I cash in my Stocks and Shares ISA?

With interest rates rising and corporate profits struggling, share prices have been coming down. So with my Stocks and Shares ISA still...

Sam Bankman-Fried is said to hire defense attorney as FTX gets hit with probes

Michael M. Santiago/Getty Images News Sam Bankman-Fried, the founder of the now-bankrupt FTX (FTT-USD) cryptocurrency exchange, has hired...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Ukraine’s strategy to combat Putin’s winter offensive: ‘We need to win this war as soon as possible’

The temperatures are frigid this time of year in Kyiv, Ukraine. But nearly half of the region’s civilians are without heat or electricity...

Coinbase CEO Slams Sam Bankman-Fried for Blaming FTX’s $8 Billion Hole on ‘Accounting Error’ – Featured Bitcoin News

The chief executive of the Nasdaq-listed cryptocurrency exchange Coinbase, Brian Armstrong, has slammed former FTX CEO Sam Bankman-Fried (SBF) for claiming that FTX...

Business News LIVE Today: Latest Business News, Share Market News, Economy & Finance News | Moneycontrol

By Market Capitalisation. Net Sales. Net Profit. Total Assets. Excise. Other Income. Raw Materials. Power & Fuel. Employee Cost. PBDIT. Interest. Tax. EPS. Investments. Sundry Debtors. Cash/Bank. Inventory. Debt. Contingent Liabilities. Screen Crit Abrasives Aerospace & Defence Agriculture Air Conditioners Airlines Aluminium & Aluminium Products Amusement Parks/Recreation/Club Aquaculture Auto Ancillaries Auto Ancillaries -...

Recent Comments